Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Matrixyl (Palmitoyl Pentapeptide): Evidence Summary
Evidence summary for Matrixyl (Palmitoyl Pentapeptide) across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Matrixyl (Palmitoyl Pentapeptide) overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Wrinkle reduction | Tier B | 10 | Multiple RCTs show 10-30% wrinkle depth reduction vs baseline over 8-12 weeks |
| Collagen stimulation | Tier C | 5 | In vitro and ex vivo data show 100-200% collagen I increase; in vivo confirmation limited |
| Skin firming / elasticity | Tier C | 3 | Some trials show elasticity improvement but outcome measures vary |
References (2)
- Efficacy of palmitoyl pentapeptide-4 in facial skin aging — Lintner K, Peschard O, Colotte M . International Journal of Cosmetic Science (2007) PMID: 18492182
- Systematic review of topical peptides in cosmetic anti-aging — Various . Journal of Cosmetic Dermatology (2018) PMID: 37335808